David A. Siegel Ligand Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 4,300 shares of LGND stock, worth $364,597. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,300

Previous 5,400 20.37%

Holding current value

$364,597

Previous $385,000 18.44%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$68.64 - $89.2 $75,504 - $98,120	-1,100 Reduced 20.37%	4,300 $314,000
Q4 2023 Feb 14, 2024	SELL	$49.57 - $72.63 $59,484 - $87,156	-1,200 Reduced 18.18%	5,400 $385,000
Q3 2023 Nov 14, 2023	SELL	$58.86 - $72.67 $58,860 - $72,670	-1,000 Reduced 13.16%	6,600 $395,000
Q2 2023 Aug 14, 2023	SELL	$69.53 - $79.33 $55,624 - $63,464	-800 Reduced 9.52%	7,600 $547,000
Q1 2023 May 15, 2023	SELL	$65.67 - $77.08 $203,577 - $238,948	-3,100 Reduced 26.96%	8,400 $617,000

Q4 2022 Feb 14, 2023	BUY	$61.72 - $96.74 $549,308 - $860,986	8,900 Added 342.31%	11,500 $768,000
Q3 2022 Nov 14, 2022	SELL	$0.01 - $107.56 $1 - $10,756	-100 Reduced 3.7%	2,600 $224,000
Q2 2022 Aug 15, 2022	BUY	$74.52 - $117.06 $37,260 - $58,530	500 Added 22.73%	2,700 $241,000
Q1 2022 May 16, 2022	BUY	$94.99 - $151.56 $28,497 - $45,468	300 Added 15.79%	2,200 $247,000
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $242,611 - $315,115	1,900 New	1,900 $293,000
Q2 2021 Aug 16, 2021	SELL	$113.03 - $155.64 $2.59 Million - $3.56 Million	-22,872 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $3.51 Million - $7.62 Million	-35,300 Reduced 60.68%	22,872 $3.49 Million
Q4 2020 Feb 16, 2021	SELL	$80.55 - $106.05 $9.17 Million - $12.1 Million	-113,800 Reduced 66.17%	58,172 $5.79 Million
Q3 2020 Nov 16, 2020	SELL	$89.56 - $126.72 $2.08 Million - $2.94 Million	-23,200 Reduced 11.89%	171,972 $16.4 Million
Q2 2020 Aug 14, 2020	BUY	$68.28 - $123.65 $225,324 - $408,045	3,300 Added 1.72%	195,172 $21.8 Million
Q1 2020 May 15, 2020	SELL	$63.37 - $107.88 $3.75 Million - $6.39 Million	-59,200 Reduced 23.58%	191,872 $14 Million
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $1.33 Million - $1.56 Million	-13,700 Reduced 5.17%	251,072 $26.2 Million
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $4.67 Million - $6.5 Million	-54,100 Reduced 16.97%	264,772 $26.4 Million
Q2 2019 Aug 14, 2019	SELL	$107.38 - $129.34 $1.03 Million - $1.24 Million	-9,600 Reduced 2.92%	318,872 $36.4 Million
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $16.4 Million - $22.1 Million	154,800 Added 89.13%	328,472 $41.3 Million
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $2.65 Million - $5.63 Million	20,684 Added 13.52%	173,672 $23.6 Million
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $7.31 Million - $9.5 Million	-34,600 Reduced 18.44%	152,988 $42 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $5.37 Million - $7.4 Million	35,600 Added 23.42%	187,588 $38.9 Million
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $19.2 Million - $25.3 Million	138,300 Added 1010.37%	151,988 $25.1 Million
Q4 2017 Feb 14, 2018	BUY	$128.36 - $147.04 $1.16 Million - $1.32 Million	9,000 Added 191.98%	13,688 $1.87 Million
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $566,826 - $646,662	4,688	4,688 $638,000

Others Institutions Holding LGND

# of Institutions

234

Shares Held

16.5M

Call Options Held

77.9K

Put Options Held

25K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.43B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account